RTW Investments is a life sciences-focused venture capital firm that invests in innovative therapies and technologies across private and public companies. Their strategy often involves a long-term, active approach, including incubating or founding new ventures.
Portfolio
7
Fund Size
$6B
Top Stage
Series A
Last 12 Mo
1
Team
SB
Scott Band, CPA
Managing Director, Tax
RA
Robert Aurigema
Partner, Chief Operating Officer and Chief Financial Officer
LG
Luc Ghaleb
Associate
OA
Ovid Amadi
Senior Analyst
Stage Distribution
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Corxel Pharmaceuticals | Series D | $287M | Jan 2026 |
| Numab Therapeutics AG | Series C | $55M | Jan 2025 |
| Ottimo Pharma | Series A | $140M | Dec 2024 |
| Kailera Therapeutics | Series A | $400M | Oct 2024 |
| Kailera Therapeutics | Growth | $400M | Oct 2023 |
| Mineralys Therapeutics, Inc. | Series B | $118M | Jun 2022 |
| Jade Biosciences | Series C | $95M | — |
Top Co-Investors
Atlas Venture2 shared
OrbiMed1 shared
Invus1 shared
Bain Capital Life Sciences1 shared
RA Capital Management1 shared
Andera Partners1 shared
Rock Springs Capital1 shared
SR One1 shared
Sectoral Asset Management1 shared
Samsara BioCapital1 shared
Adams Street1 shared
Bain Capital Ventures1 shared
Frazier Life Sciences1 shared
Versant Ventures1 shared
Venrock Healthcare Capital Partners1 shared
Deep Track Capital1 shared
Franklin Templeton1 shared
Braidwell LP1 shared
Cormorant Asset Management1 shared
Forbion1 shared
Last updated: 1 March 2026